Caroline Baumal, MD
Uveitis and Ocular Inflammatory Disease · Boston, MANPI 1891759106
Payments from drug & device makers
Across 669 payments — averaging $3006.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$945K
- Apellis Pharmaceuticals, Inc.$393K
- Genentech USA, Inc.$177K
- Novartis$128K
- Regeneron Healthcare Solutions, Inc.$125K
- Regeneron$54K
- plus $190K from 22 others
Across 4 payments — averaging $4476.44 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$18K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 107 | $944,584 |
| Apellis Pharmaceuticals, Inc. | 109 | $393,029 |
| Genentech USA, Inc. | 114 | $176,980 |
| Novartis | 85 | $127,659 |
| Regeneron Healthcare Solutions, Inc. | 64 | $124,917 |
| Regeneron | 13 | $54,428 |
| Alcon | 54 | $39,623 |
| Novartis Pharma AG | 5 | $33,748 |
| F. Hoffmann-la Roche AG | 10 | $26,726 |
| Eyepoint US, Inc. | 20 | $23,800 |
| Carl Zeiss Meditec, Inc. | 17 | $18,103 |
| AbbVie(2 entities) | 27 | $15,865 |
| Dutch Ophthalmic, USA | 9 | $11,637 |
| Thrombogenics, Inc. | 2 | $6,250 |
| Alcon Research LLC | 6 | $4,592 |
| Bausch & Lomb Americas Inc. | 8 | $4,040 |
| Biogen | 2 | $2,831 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $1,545 |
| Topcon Healthcare, Inc. | 1 | $252 |
| Neurotech Pharmaceuticals, Inc. | 1 | $234 |
| Alimera Sciences, Inc. | 4 | $186 |
| Carl Zeiss Meditec USA, Inc. | 1 | $131 |
| Dompe US, Inc. | 1 | $120 |
| Sun Pharmaceutical Industries Inc. | 1 | $114 |
| Tarsus Pharmaceuticals, Inc. | 2 | $61 |
| Boehringer Ingelheim | 1 | $56 |
| Amgen | 1 | $53 |
| Rayner Intraocular Lenses Limited | 1 | $27 |
How this compares
Too few uveitis and ocular inflammatory disease providers in Massachusettsto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other uveitis and ocular inflammatory disease in Boston
- Nadia WaheedBoston$1.1M
- Elias ReichelBoston$950K
- Lana RifkinBoston$106K
- Jay DukerBoston$22K
- Andrew TyeBoston$918
- Sarkis SoukiasianBurlington$196
- Arnold KrollMilford$118
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.